According to a recent FMI study, the global Fuchs Endothelial Corneal Dystrophy (FECD) market will grow at a 7.5% CAGR from 2023 to 2033. The market is expected to be valued at US$ 370 billion by the end of the assessment period.
The primary variables impacting the market growth rate include an increase in the prevalence of Fuchs’ endothelial corneal dystrophy, an increase in the number of senior persons, and growing healthcare spending.
Furthermore, advances in medical technology, increased demand for corneal transplantation, and rising attempts by governmental and private organizations to raise awareness about eye disorders and corneal donation are factors that will propel the Fuchs’ endothelial corneal dystrophy market forward. An increase in research on cellular treatment techniques and rising demand for eye care would benefit the Fuchs’ endothelial corneal dystrophy market during the forecast period.
Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16243
However, the high expense of therapy and the risks involved with surgical intervention will stifle market expansion. During the projection period, a lack of donor grafts would provide further challenges to Fuchs’ endothelial corneal dystrophy market. Because to the presence of leading key players, high disposable income, and sophisticated healthcare infrastructure in this area, North America leads the Fuchs’ Endothelial Corneal Dystrophy (FECD) market.
Key Takeaways from the Market Study
- FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
- The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion
- The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion
- As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.
- North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.
- The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.
“Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance,” says an analyst at FMI
Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16243
Market Competition
- Kowa Pharmaceuticals
- Trefoil Therapeutics
- Alcon
- Emmecell
- Santen
- AJL Ophthalmic SA
- Massachusetts Eye and Ear
- KeraMed, Inc.
- Presbia Plc
In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.
Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey
By Treatment:
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
By Diagnosis:
- Slit-lamp Examination
- Molecular Genetic Tests
- Pachymetry
By End User:
- Hospitals
- ASCs
- Others
To Buy this Report Visit @ https://www.futuremarketinsights.com/checkout/16243
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs